# KEYNOTE-992 (NCT04241185)

> Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04241185
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Urinary Bladder Neoplasms
- Interventions: Pembrolizumab; Conventional Radiotherapy (Bladder only); Conventional Radiotherapy (Bladder and pelvic nodes); Hypofractionated Radiotherapy (Bladder only); Cisplatin; Fluorouracil (5-FU); Mitomycin C (MMC); Gemcitabine; Placebo to Pembrolizumab
- Enrollment: 520
- Primary outcome: Bladder Intact Event-Free Survival (BI-EFS)

## Indexed commentary on KEYNOTE-992 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 8
- X threads: 8
- Podcasts: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-992-nct04241185

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04241185", "email": "<work email>"}; the inbox owner confirms by the emailed link.